Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Non-Current Assets (2021 - 2025)

Senti Biosciences has reported Non-Current Assets over the past 5 years, most recently at $27.9 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 28.11% year-over-year to $27.9 million; the TTM value through Dec 2025 reached $136.1 million, down 19.16%, while the annual FY2025 figure was $27.9 million, 28.11% down from the prior year.
  • Non-Current Assets for Q4 2025 was $27.9 million at Senti Biosciences, down from $34.5 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $230.1 million in Q1 2022 and troughed at $27.9 million in Q4 2025.
  • A 5-year average of $78.9 million and a median of $48.3 million in 2023 define the central range for Non-Current Assets.
  • On a YoY basis, Non-Current Assets climbed as much as 114.23% in 2022 and fell as far as 74.59% in 2022.
  • Year by year, Non-Current Assets stood at $36.5 million in 2021, then soared by 114.23% to $78.2 million in 2022, then tumbled by 38.27% to $48.3 million in 2023, then fell by 19.48% to $38.9 million in 2024, then dropped by 28.11% to $27.9 million in 2025.
  • Business Quant data shows Non-Current Assets for SNTI at $27.9 million in Q4 2025, $34.5 million in Q3 2025, and $36.0 million in Q2 2025.